NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Background: Quantitative mass spectrometry-based proteomics is a crucial driver for neurodegenerative biomarker discovery. In Parkinson's disease research, identifying low-abundance proteins in plasma or cerebrospinal fluid such as Alpha-synuclein and Apolipoprotein is crucial for early diagnosis. However, these important target biomarkers are highly susceptible to left-censoring (Missing Not At Random, MNAR) when their expression falls below the instrument's Limit of Detection (LoD). Conventional imputation methods, including k-Nearest Neighbors (kNN) and Bayesian Principal Component Analysis, assume random missingness, thus introducing severe bias and overestimating the levels of low-abundance proteins.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.